肿瘤转化医学研究

肿瘤耐药、复发与转移

衰老与肿瘤

1981-1986: 学士，天津医科大学临床医学系

1997-1998: 硕士，Old Dominion University & East Virginia Medical School 免疫学专业

1998-2001: 博士， University of Michigan 病理学专业

1986.08-1995.01  天津市第三人民医院/天津市老年医学研究所内科住院医师、主治医师

1995.02-1996.08  美国威斯康星-麦迪逊大学老年医学研究所/世界卫生组织奖学金访问学者

1996.09-1998.08  东弗吉尼亚医学院Glennan 老年医学研究中心Visiting Research Scientist

1998.08-2004.06  美国密歇根大学医学院博士在学/助理研究员

2004.07-2010.12  美国匹兹堡大学和密歇根大学医学院助理教授 (Tenure track)

2011.01-2016.07  长寿与老年相关疾病教育部重点实验室/转化医学研究中心主任/特聘教授

2016.07-2019.07  南方科技大学医学院筹建办执行主任/教授

2020.10-至今      南方科技大学医学院教授, 致诚书院院长

2022. 03-至今  南方科技大学伦敦国王学院医学院副院长

1994- Fellowship Award, World Health Organization (WHO)

2000-Plenary Poster Award of 22nd Annual Meeting of American Society for Bone and Mineral Research    

2002-Alice L. Jee Memorial Young Investigator Award

2003-Scholar-in-Training Award, AACR

2003- Plenary Poster Award of 25^th Annual Meeting of American Society for Bone and Mineral Research     

2005-Mentoring Dr. Yi Lu, Scholar-in-Training Award, AACR

2007-Mentoring Dr. Yi Lu, Young Investigator Travel Award, ASBMR

2013-International lecturer, Society for Basic Urology Research (SBUR)

2013-全国优秀科技工作者称号

2014-国务院政府特殊津贴获得者

2014-国家百千万人才工程国家级人选、有突出贡献中青年专家

2016-深圳市引进国家级领军人才(A类)

2018-南方科技大学优秀书院导师奖

2019-南方科技大学优秀服务奖

2020-南方科技大学优秀书院导师奖

2021-南方科技大学招生先进个人

Journals Ad hoc reviewer（受邀审稿人）

Journal of Gerontology; Biological Sciences; Bone; Cancer Research; The Prostate; Journal of Clinical Investigation; Clinical Cancer Research; Neoplasia; Molecular Cancer Research; Journal Bone Mineral Research; International Journal of Cancer; British Journal of Cancer; Molecular Cancer Therapeutics; Peptides; Journal of Cellular and Molecular Medicine;  Cancer Immunology Therapeutics; Cancer Metastasis Reviews;  Carcinogenesis; Oncotarget

Associate Editor (副主编)

 Medical Oncology; Chinese Journal of Cancer

Editorial board member （编委）

              The Open Prostate Cancer Journal; Chinese Journal of Lung Cancer; Thoracic Cancer

1. Zhang J, Dai J, Qi Y, Lin D, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 107:1235-1244, 2001.

2. Zhang J, Johnston G, Stebler B, Keller ET. Oxidative stress-mediated activation of NFkB and the interleukin-6 promoter requires NFkB-inducing kinase activity. Antioxidant & Redox Signaling. 3:493-504, 2001.

3. Zhang J, Dai J, Lin D, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. J Bone Miner Res 17:1256-1263, 2002.

4. Zhang J, J Dai, Yao Z, Lu Y, Dougall W, Keller ET. Soluble RANK-Fc diminishes prostate tumor progression in bone. Cancer Res. 63:7883-90, 2003

5. Zhang J, Lu Y, Kitazawa R, Kitazawa S, Dai J, Qi W, Zhao X, Yao Z, Hall D, Keller ET. Bioluminescence imaging of RANK ligand transcriptional regulation in vivo. Prostate. 59:360-9, 2004

6. Zhang J, Dai J, Lu Y, Yao Z, O’Brein C, Qi W, Hall D, Ershler WB, Keller ET. In vivo visualization of aging-associated gene transcription: evidence for free radical theory of aging. Experimental Gerontology. 39:239-247, 2004

7. Lu Y, Cai Z, Galson DL, Xiao G, Liu YL, George D, Melhem MF, Yao Z and Zhang J*. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate. 66:1311-8, 2006

8. Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J*. Monocyte chemotactic protein-1 (MCP-1) mediates prostate cancer-induced bone resorption. Cancer Res, 67:3646-53, 2007

9. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, and Zhang J*.   CCR2 expression correlates with prostate cancer progression. J Cell Biochem. 101:676-685, 2007

10. Lu Y, Yao Z, and Zhang J*. Prostate cancer bone metastasis: interaction between tumor cells and bone microenvironment. Chin J of Biochem and Molecul Biol, 23(3):167-171, 2007

11. Lu Y, Xiao G, Galson DL, Nishio Y, Mizokami A, Yao Z, and Zhang J*. PTHrP-induced MCP-1 production by human bone marrow endothelial cells promotes osteosteoclastast differentiation and prostate cancer cell proliferation and invasion in vitro.   Int J of Cancer. 121:724-733, 2007

12. Lu Y, Nie DB, Witt WT, Chen Q, Shen M, Xie H, Lai L, Dai Y, Zhang J*. Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3β phosphorylation. Mol Cancer Therapeutics, 7(10):3203-11, 2008

13. Lu Y, Wang J, Xu Y, Koch AE., Cai Z, Chen X, Galson DL, Taichman RS, and Zhang J*. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol Cancer Res, 6(4): 546-54, 2008

14. Lu Y, Chen QY, Corey E, Xie W, Fan J, Dai J, Mizokami A, and Zhang J*. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis, 26(2):161-9, 2009

15. Cai Z, Chen QY, Chen J, Lu Y, Xiao GZ, and Zhang J*. MCP-1 promotes lung cancer-induced bone resorptive lesions in vivo. Neoplasia, 11(3):228-236, 2009

16. Zhang J, Patel L, and Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 21(1):41-8, 2010

17. Zhang J, Lu Y, and Pienta KJ. Multiple roles of CC chemokine ligand 2 (CCL2) in promoting prostate cancer growth. J Natl Cancer Inst. 102(8):522-8, 2010

18. Zhang J*, Sud S, Mizutani K, Gyetko MR, and Pienta KJ. Activation of urokinase plasminogen activator (uPA) and its receptor (uPAR) axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia 2011

19. Zhang J, Patel L, Pienta KJ. Targeting Chemokine (C-C motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinic. Progress in Molecular Biolology: Translational Sciences. 2010;95:31-53.

20. Guo H, Yun C, Hou G, Du J, Huang X, Lu Y, Keller ET, Zhang J*, Deng J*，Mangiferin attenuates Th1/Th2 cytokine imbalance in an ovalbumin-induced asthmatic mouse model. Plos One. 9(6):e100394, 2014

21. Guo H, Lu Y, Wang J, Liu X, Keller ET, Liu Q, Zhou Q, Zhang J*. Targeting Notch Signaling Pathway in Cancer Therapeutics. Thoracic Cancer, 2014, 5; 473-86

22. Hongwei Guo, Xiaolin Zhou, Yi Lu, Liye Xie, Qian Chen, Evan T. Keller, Qian Liu, Qinghua Zhou* , and Zhang J*. Translational progress on tumor biomarkers. Thoracic Cancer. 27 JUL 2015, DOI: 10.1111/1759-7714.12294

23. Yu Zhu, Chunlin Zou, Zhe Zhang, Chaonan Qian, Xin Yang, Junlin Shi, Yudui Xia,  Zhang J*, Yi Lu*. MEK inhibitor diminishes nasopharyngeal carcinoma (NPC) cell growth and NPC-induced osteoclastogenesis via modulating CCL2 and CXCL16 expression. Tumor Biology, 2015, 36(11):8811-8.

24. Sha He, Yi Lu, Xia Liu, Xin Huang, Evan Keller, Chao-Nan Qian*,  Zhang J*; Wnt3a: function and implication in cancer. Chinese Journal of Cancer, 2015, 34(3):50.

25. Lihui Wang, Yanli He, Weijun Liu, Shengbin Bai, Lei Xiao, Jie Zhang, Saravana M. Dhanasekaran, Zhuwen Wang, Shanker Kalyana-Sundaram, O. Alejandro Balbin, Sudhanshu Shukla, Yi Lu, Jules Lin, Rishindra M. Reddy, Philip W. Carrott, Jr., William R. Lynch, Andrew C. Chang, Arul M. Chinnaiyan, David G. Beer*, Zhang J*, Guoan Chen*. Non-coding RNA LINC00535 promotes lung adenocarcinoma progression via the Akt pathway. Oncotarget, 7(10):11487-99, 2016.

26. Jing Li, Xin Yang, Hao Guan, Atsushi Mizokami, Evan T. Keller, Xiaozhen Xu, Xia Liu, Jiyong Tan, Longyuan Hu, Yi Lu*, Zhang J*. Exosome-derived microRNAs contribute to prostate cancer chemoresistance. International Journal of Oncology, 2016, 49:838-846.

27. Yeguo Yang, Yi Lu, Lihui Wang, Atsushi Mizokami, Evan T. Keller, Zhang J*, Jiejun Fu*. Skp2 inhibition attenuates the resistance of prostate cancer cells to paclitaxel by up-regulation of p27. Oncology Reports, 2016, 36:559-566.

28. Yang Liu, Yi Chai, Zhang J*, and Junwei Tang*. A function variant at miR-501 alters susceptibility thepatocellular carcinoma in a Chinese han population. Cell Physiol Biochem, 38(6):2500-8, 2016.

29. Qiuyan Chen, Siyuan Qin, Yang Liu, Minghuang Hong, Chao-Nan Qian, Evan T Keller, Zhang J, Lu Y*. IGFBP-6 is a novel nasopharyngeal carcinoma prognostic biomarker. Oncotarget, 2016, Oct 18;7(42):68140-68150.

30. Yong Lei, Yanhua Yi, Yang Liu, Xia Liu, Evan T. Keller, Chao-Nan Qian, Jian Zhang* and Lu Y*. Metformin targets multiple signaling pathways in cancer. Chinese Journal of Cancer, 2017; 36(1):17.

31. Guo H, Luo H, Yuan H, Xia Y, Shu P, Huang X, Lu Y, Liu X, Keller ET, Sun D*, Deng J*, and Zhang J*. Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3β signaling. Sci Rep. 2017; 7: 41656.

32. Wenchu Wang, Lihui Wang, Atsushi Mizokami, Junlin Shi, Chunlin Zou, Jinlu Dai, Evan T. Keller, Yi Lu* and Jian Zhang*. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chinese Journal of Cancer, 2017; 36:35

33. Yutao Gao, Xia Liu, Ting Li, Luwei Wei, Antai Yang, Yi Lu, Jian Zhang, Li Li, Sumei Wang and Fuqiang Yin. Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer. Oncology Reports. 2017

34. Jinlu Dai, Yi Lu, Hernan Roca, Jill M. Keller, Jian Zhang, Laurie K. McCauley and Evan T. Keller. Immune mediators in the tumor microenvironment of prostate cancer. Chinese Journal of Cancer, 2017; 36:29